CClinicalTrials.gg
RecruitingNCT06127849Updated Feb 1, 2024

A Study to Evaluate Efficacy of EB-PA as Protein Amplifier for Skeletal Muscle Strength & Growth

An interventional study of Resistance Training + Placebo (Capsule) + Placebo (Sachet) and Resistance Training + Whey protein (40 gms) + Placebo (Capsule) in Skeletal Muscle Strength & Growth, sponsored by Vedic Lifesciences Pvt. Ltd.. Recruiting at 3 sites in India. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Vedic Lifesciences Pvt. Ltd. · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

The present study is a randomized, placebo-controlled, double blinded study to evaluate efficacy of EB-PA as protein amplifier for skeletal muscle strength \& growth in males with active lifestyle. Approximately 160 subjects aged between ≥ 20 and ≤ 35 years will be screened and 138 participants are to be randomized. Both the IP and placebo study arms will have at least 40 completed subjects after accounting for the screening failure and dropout/withdrawal rate of 14% and 13 % respectively (Total 120 completers). The treatment duration for all the study subjects will be 30 days. The sustained effect of the product will be observed for next 7 days, wherein, the subjects will be abstaining from the protein and IP supplementation and will exercise at their ease.

02

Conditions studied

  • Skeletal Muscle Strength & Growth
03

In context

Lead sponsor

Vedic Lifesciences Pvt. Ltd. is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Males aged 20 - 35 years with active lifestyle with moderate physical activity level as per International Physical Activity Questionnaire.
  • Recreationally gym goer with history of at least 1 month of endurance training (E.g.: functional exercises)
  • Not participating in resistance type training (E.g.: external or body weight training) for ≥3 months prior to screening.
  • Body mass index (BMI) 22 - 29.9 kg/ m2.
  • Individuals with a 1-RM strength defined by Upper Body ≥ 25 Kgs and Lower Body ≥ 100 Kgs will be included in the study.
  • Ready to refrain from caffeinated products and intense strength/ endurance exercise for 24 hrs prior to the exercise lab visit.
  • Fasting Blood Glucose ≤ 110 mg/ dl.
  • Systolic Blood Pressure ≤ 129 mmHg and Diastolic Blood Pressure ≤ 89 mmHg.
  • TSH (thyroid stimulating hormone) ≥ 0.4 and ≤ 4.9 mIU/L.

Exclusion criteria

Exclusion Criteria:

  • Engaged in structured weight training for more than 3 months prior to screening.
  • Presence of chronic disease.
  • Changes in body weight more than 4.5 kg (10 pounds) in the past three months as assessed by history.
  • Subjects diagnosed with hypertension.
  • Subjects who are diagnosed with Type I Diabetes Mellitus and Type II Diabetes Mellitus.
  • History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders.
  • Allergy to whey protein or herbal ingredients.
  • Subjects who have any other disease or condition, or are using any medication, that in the judgment of the investigator would put them at unacceptable risk for participation in the study or may interfere with evaluations in the study or noncompliance with treatment or visits.
  • Subjects who have been part of a clinical study within 90 days prior to the screening.
  • Subjects who have used whey or other supplemental proteins anytime in last 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
138 participants (estimated)

Study arms

  • Placebo comparator
    Resistance Training + Placebo (Capsule) + Placebo (Sachet)

    A sachet of 20 gms of Placebo dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening. One capsule of placebo to be taken 30 minutes after placebo sachet in the morning.

    Dietary Supplement: Resistance Training + Placebo (Capsule) + Placebo (Sachet)

  • Active comparator
    Resistance Training + Whey protein (40 gms) + Placebo (Capsule)

    A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening. One capsule of Placebo to be taken 30 minutes after whey protein in the morning.

    Dietary Supplement: Resistance Training + Whey protein (40 gms) + Placebo (Capsule)

  • Active comparator
    Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)

    A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening. One capsule of EB0-PA to be taken 30 minutes after whey protein in the morning.

    Dietary Supplement: Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)

Interventions

  • Dietary supplementResistance Training + Placebo (Capsule) + Placebo (Sachet)

    * Placebo sachet of 20 gms dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening. * One Placebo capsule to be taken 30 minutes after sachet in the morning.

  • Dietary supplementResistance Training + Whey protein (40 gms) + Placebo (Capsule)

    A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening. - One Placebo capsule to be taken 30 minutes after whey protein in the morning

  • Dietary supplementResistance Training + Whey protein (40 gms) + EB-PA (500 mg)

    * A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening. * One capsule of EB-PA to be taken 30 minutes after whey protein in the morning

06

What researchers measure

Primary outcomes

  1. To assess improvement in muscle strength after administration of Investigational Product (IP) as assessed by increase in lower body 1 RM (repetition maximum) weight from baseline.

    The maximum weight that can be lifted once with the correct lifting technique is known as the 1-RM. The 1-RM will be determined by the Brzycki equation using calculator as follows: Weight ÷ \[1.0278 - (0.0278 × Number of repetitions)\].

    Time frame: Day 30

  2. To assess improvement in muscle strength after administration of Investigational Product (IP) as assessed by increase in upper body 1 RM (repetition maximum) weight from baseline.

    The maximum weight that can be lifted once with the correct lifting technique is known as the 1-RM. The 1-RM will be determined by the Brzycki equation using calculator as follows: Weight ÷ \[1.0278 - (0.0278 × Number of repetitions)\].

    Time frame: Day 30

Secondary outcomes

  1. To assess the effect of Investigational Product (IP) on Increase in muscle endurance as assessed by increase in exercise volume calculated as load x number of repetition (upper + lower body exercise) completed at ≥70% of screening 1-RM.

    The maximum weight that can be lifted once with the correct lifting technique is known as the 1-RM. The 1-RM will be determined by the Brzycki equation using calculator as follows: Weight ÷ \[1.0278 - (0.0278 × Number of repetitions)\].

    Time frame: Day 0 to Day 30

  2. To assess the effect of Investigational Product (IP) on Increase in muscle (hamstring) flexibility as assessed by increase in distance for V sit & reach test.

    V sit and reach test is performed to measure the flexibility of the lower back and back thigh muscles.

    Time frame: Day 0 to Day 30

  3. To assess the effect of IP on improvement in muscle mass as indicated by increase in fat free mass (FFM), lean muscle mass and android fat by DXA.

    Total body scans will be performed using a device with its scan mode already determined automatically by the device operating system within the manufacture specification.

    Time frame: Day 0 to Day 30

  4. To assess the effect of IP on improvement in grip strength as indicated by increase in non-dominant hand grip strength.

    Each subject will perform the test three times approximately with 25±5 sec relaxations between the session. The participant should be instructed to squeeze the dynamometer until the grip is stable. For 3 sets, the reading will be noted in Kg and an average of 3 readings will be calculated.

    Time frame: Day 0 to Day 30

  5. To assess the effect of IP on Improvement in metabolic health as indicated by waist to height ratio.

    Waist circumference (WC) will be measured at the end of a normal expiration using a non-stretchable measuring tape.

    Time frame: Day 0 to Day 30

  6. To assess the sustained effect of IP on muscle strength as assessed by Maintenance of lower body 1 RM weight

    The maximum weight that can be lifted once with the correct lifting technique is known as the 1-RM. The 1-RM will be determined by the Brzycki equation using calculator as follows: Weight ÷ \[1.0278 - (0.0278 × Number of repetitions)\].

    Time frame: Day 30 To 37

  7. To assess the sustained effect of IP on muscle strength as assessed by Maintenance of upper body 1RM weight

    The maximum weight that can be lifted once with the correct lifting technique is known as the 1-RM. The 1-RM will be determined by the Brzycki equation using calculator as follows: Weight ÷ \[1.0278 - (0.0278 × Number of repetitions)\].

    Time frame: Day 30 To 37

07

Study locations

3 of 3 sites recruiting
  • Dr. Khare's Clinic
    Mumbai, Maharashtra 400053, India
    Recruiting
  • Nirmala Clinic
    Mumbai, Maharashtra 400101, India
    Recruiting
  • Dr. Preeti Bawaskar's Clinic
    Thane, Maharashtra 400607, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06127849
Lead sponsor
Vedic Lifesciences Pvt. Ltd.
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Nov 28, 2023
Primary completion
Mar 31, 2024 (estimated)
Completion
Jun 5, 2024 (estimated)
Last update
Feb 1, 2024

Study contacts

Dr. Shalini Srivastava, MBBS, MD
Contact
shalini.s@vediclifesciences.com
02242172300
Dr. Sonali Ghosh,, BAMS
Contact
sonali.g@vediclifesciences.com
02242172300

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion